Apomorphine, under the brand name Apokyn ... injection using only the multiple-dose APOKYN Pen with the supplied cartridges. One of the hallmarks of Parkinson's disease is the gradual depletion ...

February is observed as American Heart Month, a period dedicated to raising awareness about heart health. The first American Heart ...

If your turntable setup is in need of a refresh, it's worth considering changing the current cartridge rather than swapping out the entire record player itself. It's a simple but effective change, and ...

Learn more With the hopes of luring hunters to something fresh, innovative, and different, we see new rifle cartridges introduced almost every year. The grass is always greener, right? New ...

The company has confirmed that the just-announced Switch 2 device will support cartridges from the original Switch. The news shouldn’t be too surprising. Late last year, Nintendo confirmed that ...

Onapgo, a subcutaneous apomorphine infusion device, is approved for advanced Parkinson's disease, offering continuous symptom management without surgery. The TOLEDO trial showed apomorphine ...

“Continuous subcutaneous apomorphine infusion already has a proven and established 30-year history in Europe, where it has helped deliver more consistent control of motor fluctuations for ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease ONAPGO is a wearable subcutaneous ...

Supernus Pharmaceuticals has announced the FDA approval of ONAPGO, the first subcutaneous apomorphine infusion device specifically designed to treat motor fluctuations in adults with advanced ...

THURSDAY, Feb. 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion ...

Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...